LONDON, March 1, 2016 /PRNewswire/ -- Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is showcasing the new REDAPT™ Revision Acetabular Fully Porous Cup with CONCELOC™ Technology at this week's American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Orlando.
The new REDAPT cup is designed for use in revision cases where compromised bone makes implant fixation and stability more difficult. To allow ingrowth, an additive, or 3D, manufacturing process is used to produce an entirely porous implant that mimics the structure of cancellous bone and new variable-angle locking screws can be used to enhance implant stability and minimize micromotion after surgery.
"We're excited about the creative possibilities this new manufacturing process holds for surgeons and their patients," said Mike Donoghue, Vice President of Global Reconstruction at Smith & Nephew. "Bringing to market a 3D-printed titanium acetabular cup for difficult revision procedures is just one example of the potential of this remarkable technology."
The CONCELOC Advanced Porous Titanium technology is an alternative to external porous coatings, such as sintered beads or fiber mesh used in other uncemented implants, to allow bone ingrowth securing the implant in place.
Successful fixation of a porous implant requires that the implant remains in steady, stationary contact with the bone as it heals and new bone grows. For this reason, the new REDAPT cup also uses the new REDAPT Variable Angle Locking Screws, which work within the implant's unique geometry to provide both compression and a rigid construct to the acetabular shell, as well as traditional, non-locking screws.
"This fully porous cup gives surgeons flexibility in ways that simply weren't possible before," said Craig Della Valle, MD, Professor of Orthopaedic Surgery at Rush University Medical Center in Chicago, who participated on the surgeon design team for the new REDAPT cup. "The locking screws, screw-in trials, purpose-built liners and screw hole patterns optimized for hard-to-access areas really set it apart during a revision procedure. This cup builds on good technology and turns it into something spectacular."
Smith & Nephew received Food and Drug Administration 510(k) clearance for the REDAPT Revision Acetabular Fully Porous Cup with CONCELOC Technology in November 2015. It is currently available in select sites in the US and can be seen this week at the Smith & Nephew booth (booth 1945) at the AAOS Annual Meeting.
About 3D manufacturing
The 3D manufacturing process used to build each new REDAPT cup begins by precisely aiming a laser onto a thin layer of titanium (Ti-6Al-4V) powder. The heat generated by the laser fuses the powder together, building upward, layer-by-layer, until a fully formed titanium implant is produced. This manufacturing method allows for complex design geometries that would be difficult, expensive or impossible to achieve with traditional manufacturing methods. For example, solid reinforcements can be built directly into the porous structure to provide extra strength in precise locations.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN,NYSE:SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew